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Background:  Evaluation of cardiovascular (CV) safety for new therapies for chronic obstructive pulmonary disease (COPD) is important as there is 
a high prevalence of cardiac co-morbidities in the COPD population. We evaluated the effects of roflumilast, a novel oral phosphodiesterase 4 (PDE-
4) inhibitor being developed for the treatment of moderate to severe COPD.
Methods:  All clinical trials of roflumilast in COPD were assessed for potential CV events; studies were comprised of fourteen 52-week placebo-
controlled trials in patients with moderate to severe COPD. All deaths and serious CV events were evaluated by an independent CV adjudication 
committee blinded to study and treatment. Results were tabulated according to treatment group and dose of roflumilast (250 and 500 ug daily). For 
the purposes of the analysis, dose groups of roflumilast were combined.
Results:  The risk of a CV event on roflumilast was low and similar to or less than placebo rates (Table). Of note, the major adverse CV event (MACE) 
composite of CV death, nonfatal myocardial infarction (MI) and stroke was lower on roflumilast (hazard ratio vs placebo, 0.65, 95% CI, 0.45-0.93, p 
= 0.019).
Conclusions:  There is a lower MACE rate on roflumilast versus placebo in patients with moderate and severe COPD. This suggests a potential 
benefit of the drug that should be evaluated in future controlled clinical trials.
Table. Major cardiovascular events in controlled roflumilast trials 
Event Rates Hazard Ratio* and 95% CI
Roflumilast N=6563
Placebo 
N=5491
Hazard ratio 95% CI p-value
Composite of Major Adverse Cardiovascular Events, N (%) 52 (0.80) 76 (1.4) 0.65 [0.45, 0.93] 0.019
CV death, N (%) 35 (0.50) 42 (0.80) 0.76 [0.49, 1.20] 0.245
Nonfatal MI, N (%) 11 (0.20) 22 (0.40) 0.55 [0.26, 1.14] 0.109
Nonfatal stroke, N (%) 6 (0.10) 12 (0.20) 0.41 [0.14, 1.17] 0.097
* calculated via Cox proportional hazard model
